Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
August 2015
-
Press Release
Novartis continues commitment to go the last mile in effort to eliminate leprosy
New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact… -
Press Release
Das Novartis International BioCamp zeigt, wie Zusammenarbeit und Vielfalt Innovationen fördern, und inspiriert künftige wissenschaftliche Führungskräfte
Das International Biotechnology Leadership Camp (BioCamp) fördert das Interesse von Studierenden für wissenschaftlichen Fortschritt und unternehmerische Chancen Anlässlich des interaktiven Programms… -
Press Release
Le Novartis International BioCamp souligne le rôle de la collaboration et de la diversité pour stimuler l'innovation et inspirer les futurs leaders scientifiques.
L'International Biotechnology Leadership Camp (BioCamp) mobilise des étudiants autour d'avancées scientifiques et d'opportunités entrepreneuriales. Ce programme interactif a réuni au siège de… -
Press Release
Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leaders
The International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities The interactive program brought 70 university students… -
Press Release
FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12… -
Press Release
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a… -
Press Release
Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC[1] Basal cell carcinoma is… -
Press Release
Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million
CSL Limited acquired influenza vaccines business of Novartis, including influenza vaccines development pipeline Basel, Switzerland, August 3, 2015 - Novartis today announced that it has completed…
July 2015
-
Press Release
Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd
Novartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds… -
Press Release
Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt
Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School… -
Press Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin… -
Press Release
Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones
CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for…